Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5

Benzinga Newsdesk www.benzinga.com Neutral 71.6%

Neg 0% Neu 71.6% Pos 0%

Roth Capital analyst Max Masucci initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $3.5.